Godtfredsen v. Banner

598 F.2d 589, 202 U.S.P.Q. (BNA) 7, 1979 CCPA LEXIS 250
CourtCourt of Customs and Patent Appeals
DecidedMay 24, 1979
DocketAppeal No. 79-514
StatusPublished
Cited by8 cases

This text of 598 F.2d 589 (Godtfredsen v. Banner) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Godtfredsen v. Banner, 598 F.2d 589, 202 U.S.P.Q. (BNA) 7, 1979 CCPA LEXIS 250 (ccpa 1979).

Opinions

BALDWIN, Judge.

Petitioner seeks writs of mandamus and prohibition directing the Commissioner of Patents and Trademarks to:

(1) substitute Count A (reciting a Markush group of compounds) as set forth in Petitioner’s “Motion to Amend By Substituting A New Count for the Present Count,” filed December 7, 1976, as the sole count in interference; and
(2) prohibit the interference from proceeding as currently constituted with counts 1, 2 and 3.
The Petition is dismissed.

Background

Interference 99,384 was declared on July 7, 1976, between Godtfredsen application Serial No. 554,423, filed March 3, 1975, and Bamberg et al. application Serial No. 464,-157, filed April 25, 1974. Both parties were accorded the benefits of earlier filed U.S. patent applications. Godtfredsen was designated the senior party by reason of his parent application filed April 13, 1972. The sole count in the interference declaration was directed to a method of treating bacterial infections by forming in the body a 1:1 mixture of a specific two-compound antibiotic mixture. During the motion period, Godtfredsen moved to substitute a broader count (Count A) directed to the same method, but covering the use of any of three related two-compound antibiotic mixtures, each mixture containing as. a common compound an amidopenicillanic acid (hereinafter mecillinam).

Godtfredsen also moved, contingent on the denial of the Motion to Substitute Count A, to add Count B and Count C. Counts B and C recited the two mixtures additionally found in Count A but not found in the original count.

The Primary Examiner denied the Motion to Substitute Count A noting that:

Count A is directed to three independent and distinct compositions comprising mecillinam and either (1) ampicillin (Count 1), (2) benzylpenicillin (proposed Count B) or (3) azidocillin (proposed Count C). Count A is, therefore, unpatentable since it is directed to a mixture of independent and distinct inventions under 35 U.S.C. § 121.

The Primary Examiner granted a motion by Godtfredsen to be accorded the benefit of the filing date of the corresponding British application (May 5, 1971) for Count B. He denied that motion regarding Count 1 and Count C. Bamberg et al., on the other hand, was accorded the benefit of the filing date of their British application (November 1, 1971) for each of the counts.

Godtfredsen thereupon petitioned the Commissioner, under 37 CFR 1.181,1 re[591]*591questing that he invoke his supervisory authority and reverse the examiner’s decision denying the Motion to Substitute Count A. Godtfredsen argued that the Manual of Patent Examining Procedure, § 1101.01(j), concerning Suggestion of Claims, provides in pertinent part:

In general, the broadest patentable claim which is allowable in each case should be used as the interference count and additional claims should not be suggested unless they are sufficiently different that they may properly issue in separate patents.

Godtfredsen further sought to demonstrate that the Markush group found in Count A did not recite separate inventions in that each member of that group was a commonly known penicillin. He additionally observed that during the prosecution of the Bamberg et al. application, the examiner rejected claims under 35 U.S.C. § 121 which were not only broader than Count A but included the very mixtures of compounds set forth in Count A. The party Bambert et al. argued in response that the rejection under 35 U.S.C. § 121 was improper in that the claims did not recite independent and distinct inventions.

The Commissioner, acting through the Chairman of the Board of Patent Interferences, granted the petition to the extent that it was remanded to the Primary Examiner with the instruction that he provide the basis for his conclusion in the decision on motion.

Upon remand, the examiner adhered to his prior decision and added only the reason for that decision, stating:

The proposed Count A is directed to a synergistic combination of mecillinam with (1) ampicillin (2) benzylpenicillin or (3) azidocillin. A prior art reference anticipating one synergistic combination (e. g. mecillinam/ampicillin) would not anticipate or make obvious any other synergistic combination (e. g. mecillinam/azidocillin or mecillinam/benzylpenicillin). The patentability of a combination of old elements is predicated on unexpected results termed synergism; an adequate showing must be made in each case such that synergism for one cannot be predicted from any prior showing for a different combination.

Godtfredsen again petitioned the Commissioner under 37 CFR 1.181 alleging abuse of discretion by the examiner and requesting that the Commissioner exercise his supervisory authority and instruct the examiner to substitute Count A as the sole count in the interference. In essence, the arguments and showings of the prior petition to the Commissioner were repeated.

Before the Commissioner acted on this latter petition, a supplemental petition was entered. The action was stirred by this court’s intervening decisions in In re Weber, 580 F.2d 455, 198 USPQ 328 (Cust. & Pat. App.1978) and In re Haas, 580 F.2d 461, 198 USPQ 334 (Cust. & Pat.App.1978) wherein it was held that 35 U.S.C. § 121 does not provide a basis for an examiner, acting under the authority of the Commissioner, to reject a particular claim on the basis that it contains independent and distinct inventions. Godtfredsen argued that his was but a single generic discovery and should be treated as such in the interference proceedings. It was argued that Weber and Haas [592]*592removed any basis in law the examiner may have had in refusing to substitute Count A in the manner requested.

The Commissioner, again acting through the Chairman of the Board of Patent Interferences, denied the petitions noting, first, that,

It appears that the four materials recited in the three species are all known in the art, and that patentability of the three species is predicated upon the synergistic result obtained by mixing each of the three acylamino penicillanic acids (ampicillin, benzylpenicillin and azidocillin) with mecillinam in the body in the ratio 1:1. That being the case, it is not considered that the Examiner’s conclusion that each species would be patentable over each other species was clearly erroneous.

and further that,

However, while it may well be that, in view of the Weber and Haas cases, a claim corresponding to proposed count A could not properly be rejected under 35 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Innotron Diagnostics
800 F.2d 1077 (Federal Circuit, 1986)
Sernaker v. Mossinghoff
581 F. Supp. 1548 (E.D. Pennsylvania, 1984)
McNally v. Mossinghoff
673 F.2d 1253 (Customs and Patent Appeals, 1982)
Hester v. Allgeier
646 F.2d 513 (Customs and Patent Appeals, 1981)
Fraige v. Parker
610 F.2d 795 (Customs and Patent Appeals, 1979)
Refractarios Monterrey, S.A. v. Ferro Corp.
606 F.2d 966 (Customs and Patent Appeals, 1979)
Margolis v. Banner
599 F.2d 435 (Customs and Patent Appeals, 1979)

Cite This Page — Counsel Stack

Bluebook (online)
598 F.2d 589, 202 U.S.P.Q. (BNA) 7, 1979 CCPA LEXIS 250, Counsel Stack Legal Research, https://law.counselstack.com/opinion/godtfredsen-v-banner-ccpa-1979.